These are the recordings of the Keynote Address and Plenary Sessions from the NAACCR 2024 Annual Conference available for purchase.

This instructional webinar will cover the NAACCR Call for Data process and will highlight critical changes for this year, including new data items and the required tumor-level de-duplication protocol. It is important that at least one staff person from each central registry attend. This webinar will be recorded and available for review on the Call for Data Page. Call for Data Timeline 2024: • Aug 26th CFD Instructional Webinar • Sept 1st CFD Resources available on the NAACCR Call for Data Webpage: https://www.naaccr.org/call-for-data/ • First week of Sept: Match*Pro ver 2.5 release • First week of Oct: NAACCR*Prep release (also File*Pro) • Nov 1st CFD Portal Opens • Dec 3rd NAACCR CFD Due If you have any questions, please reach out Recinda Sherman, Program Manager of Data Use and Research.

During our March roundtable, we'll review the latest updates to the Death Clearance Manual. Additionally, various registries will showcase their Death Clearance procedures, which may include utilizing Web Plus for followback and leveraging Health Information Exchange Data.

Adolescent and Young Adult (AYA) Oncology: The insights gained from the Malignant Germ Cell International Consortium (MaGIC). Dr. A. Lindsay Frazier, MD One of the most common adolescent and young adult (AYA) cancers are the cell tumors (GCTs), however no significant change has happened to GCTs treatments protocols in the last decades. The Malignant Germ Cell International Consortium (MaGIC) brings together the world’s leading experts in germ cell tumors (GCTs), from across the spectrum of cancer research, with the shared goal of developing more effective treatments for GCTs through scientific inquiry. As the lead of the Malignant Germ Cell Tumor International Consortium, Dr Lindsay will discuss AYA Oncology and share important lessons learned in the field of GCT research. Forecasting for Accurate Procurement of Pediatric Chemotherapies. Dr. Shrivastava, MD, MPH Forecasting the cost and quantities of pediatric chemotherapies is an essential part of ensuring a reliable supply of essential medicines for the care of children with cancer. Dr. Shrivastava will describe the importance of access to accurate registry data and its relevance today amongst several critical drug shortages.

Three presentations with a focus on applications of Artificial Intelligence (AI) and Natural Language Processing (NPL) in the cancer registry field.

This two-part series is presented by CDC colleagues who are on the forefront of a number of initiatives in the rapidly developing area of public health interoperability. This educational series was presented at the NAACCR annual conference in June 2023 and, due to popular demand, is being offered as a "replay" for the entire NAACCR community. These two sessions will provide an overview of key interoperability terms and an update on current initiatives that will impact public health and cancer surveillance in particular. These initiatives are intended to improve health data exchange and quality across healthcare. Topics will include benefits and potential implications for registries. There will be time for questions and answers throughout both sessions.

The NAACCR Professional Development Steering Committee Upkeep Task Force revised the Oncology Data Specialist Training Guide. This presentation will review the revisions and the goals of the guide.

This webinar will introduce Vesta, a software for visualization and exploratory space-time analysis and modeling. Developed with funding from the National Cancer Institute and the National Institute of Environmental Health Sciences, Vesta is designed to accelerate visualization, hypothesis generation, and modeling of complex, multivariate datasets that typify health-environment relationships. This webinar will also demonstrate four applications of using Vesta to answer public health questions including hypothesis generation (identification of spatial patterns for cervical mortality that account for ethnicity and poverty, visualization of late-stage breast cancer incidence) and hypothesis testing (Flint water lead levels, late-stage breast cancer incidence).

In this course, you will learn about important concepts for managing the data accumulated in a cancer registry. These include an orderly multi-step workflow that focuses on data accuracy, use of appropriate software, and recommended procedures for securing the data from threats and unauthorized use.

CONCORD: After describing world-wide surveillance of trends in cancer survival for the first time in 2015, the third cycle of the CONCORD programme (CONCORD-3) was updated to include patients diagnosed between 2000 and 2014, with follow-up to 31 December 2014. It included data for 18 cancers or haematological malignancies that collectively represented 75% of the global cancer burden in 2014. Individual patient records for over 37.5 million patients were included in the analyses. These data were provided by 322 population-based cancer registries in 71 countries and territories, of which 47 provided data with 100% national population coverage. Cancer registries in nine Canadian provinces and 42 US states contributed data for a total of 14,320,034 patients. Since 2017, the Organisation for Economic Cooperation and Development has included survival estimates from the CONCORD programme among the indicators of the effectiveness of health systems in managing cancer in all its Health at a Glance reports. VENUSCANCER: Embedded in the CONCORD programme, this is a world-wide project designed to explain the global inequalities in patterns of care, short-term survival and trends in avoidable premature deaths from breast, cervical and ovarian cancers, the three most common cancers in women. The goal of this project, funded by the European Research Council, is to provide levers for health policy to reduce or eliminate avoidable differences in survival from these cancers. During the webinar we will discuss the ongoing data submission to the VENUSCANCER project, and the recent call for data for CONCORD-4. Presentations: VENUSCANCER: Project Overview and Extend Call for Data Claudia Allemani, MSc, PhD, FHEA, MFPH London Scholl of Hygiene and Tropical Medicine SAS-Code to map NAACCR Data Structure to VENUSCANCER data specification Bozena Morawski, BA, MPH, PhD Cancer Data Registry of Idaho CONCORD-4: Scope and Ambition, and Call for Data Michel Coleman, BA, BM BCh, MSc, FFPH London School of hygiene and Tropical Medicine SAS-code to Map NAACCR Data Structure to CONCORD-4 Data Specification Christopher Johnson, MPH Cancer Data Registry of Idaho